...
首页> 外文期刊>Journal of digestive diseases >Meta-analysis: perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma.
【24h】

Meta-analysis: perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma.

机译:荟萃分析:围手术期局部肝化疗可改善结直肠癌患者的生存率并预防其肝转移。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: To evaluate the effect of prophylactic regional liver chemotherapy during the perioperative period on improving survival and preventing liver metastases in patients with colorectal cancer (CRC). METHODS: A comprehensive retrieval of the relevant literature was performed by searching major biomedical database, mainly from Medline and Embase. Studies reported in the selected literature were categorized into two subgroups according to the type of therapy: a perioperative hepatic artery infusion subgroup and a perioperative portal vein infusion subgroup. Mortality and liver metastasis were analyzed using a fixed-effects model. Statistical analysis was performed using Review Manager software. RESULTS: The results of this meta-analysis illustrated that survival and the rate of liver metastasis in patients receiving perioperative hepatic artery infusion (HAI) chemotherapy were significantly better than for those receiving surgery alone (pooled relative risk 0.46 [95% CI: 0.31-0.69] and 0.44 [95% CI: 0.28-0.68], respectively, P= 0.0002), while survival and the rate of liver metastasis in patients receiving perioperative portal vein infusion (PVI) chemotherapy were not significantly different from those receiving surgery alone (pooled relative risk 0.98 [95% CI: 0.89-1.09], P= 0.73 and 0.86 [95% CI: 0.72-1.02], respectively. P= 0.08). CONCLUSION: As a method of regional liver chemotherapy, HAI might be able to improve survival and reduce the rate of liver metastasis in patients with advanced CRC.
机译:目的:评估围手术期预防性区域肝化疗对提高结直肠癌(CRC)患者生存率和预防肝转移的作用。方法:通过检索主要的生物医学数据库,主要是从Medline和Embase中,对相关文献进行全面检索。所选文献中报道的研究根据治疗类型分为两个亚组:围手术期肝动脉输注亚组和围手术期门静脉输注亚组。使用固定效应模型分析死亡率和肝转移。使用Review Manager软件进行统计分析。结果:这项荟萃分析的结果表明,接受围手术期肝动脉灌注(HAI)化疗的患者的生存率和肝转移率显着优于仅接受手术的患者(合并相对危险度0.46 [95%CI:0.31-分别为0.69]和0.44 [95%CI:0.28-0.68],P = 0.0002),而接受围手术期门静脉输注(PVI)化疗的患者的生存率和肝转移率与单纯接受手术的患者无显着差异(合并相对风险分别为0.98 [95%CI:0.89-1.09],P = 0.73和0.86 [95%CI:0.72-1.02]。P= 0.08)。结论:HAI可作为局部肝化疗的一种方法,可以改善晚期CRC患者的生存率并降低其肝转移率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号